World's Best Scientists 2026 revealed!
Diane F. Jelinek

Diane F. Jelinek

D-Index & Metrics

Immunology

D-Index
84
Citations
20027
World Ranking
1408
National Ranking
717

Medicine

D-Index
84
Citations
20027
World Ranking
15315
National Ranking
7727

Diane F. Jelinek publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Diane F. Jelinek sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 316 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Diane F. Jelinek D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Diane F. Jelinek sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Diane F. Jelinek is affiliated with the Mayo Clinic in the United States and has a research focus primarily in the fields of medicine, immunology and microbiology, as well as biochemistry, genetics, and molecular biology. Their work spans several subfields including immunology, genetics, oncology, hematology, and pathology and forensic medicine.

The research topics covered by Diane F. Jelinek include:

  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • Lymphoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Immune Cell Function and Interaction
  • Cancer-related molecular mechanisms research
  • Extracellular vesicles in disease

The scientist's recent publications illustrate a focus on hematologic malignancies and immune interactions. Selected papers include:

  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial, 2022, Blood
  • Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma, 2022, Blood
  • Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL, 2020, Blood
  • B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells, 2022, Blood Cancer Journal
  • Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells, 2022, Non-Coding RNA

Frequent publication venues for Diane F. Jelinek comprise Clinical Lymphoma Myeloma & Leukemia, Blood, Blood Cancer Journal, Blood Advances, and Non-Coding RNA.

The scientist has collaborated regularly with several researchers, including Renee C. Tschumper, Neil E. Kay, Denise K. Walters, Esteban Braggio, and Marta Chesi. These co-authors frequently appear across multiple publications, reflecting ongoing research partnerships.

Best Publications

  • Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

    Robert A. Kyle;Ellen D. Remstein;Terry M. Therneau;Angela Dispenzieri

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

    Anne J. Novak;Anne J. Novak;Jaime R. Darce;Jaime R. Darce;Bonnie K. Arendt;Bonnie K. Arendt;Brandon Harder;Brandon Harder

  • Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis.

    Diane F. Jelinek;Stefan Andersson;Clive A. Slaughter;David W. Russell

  • Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

    Angela Dispenzieri;Robert A. Kyle;Jerry A. Katzmann;Terry M. Therneau

  • Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997

    Michael R. Grever;David M. Lucas;Gordon W. Dewald;Donna S. Neuberg

  • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

    Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt

  • Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation

    Jaime R. Darce;Bonnie K. Arendt;Xiaosheng Wu;Diane F. Jelinek

  • Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Thomas E. Witzig;Stephanie R. Fink;Robert B. Jenkins

  • Chronic Lymphocytic Leukemia

    Neil E. Kay;Terry J. Hamblin;Diane F. Jelinek;Gordon W. Dewald

  • Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

    Gordon W. Dewald;Stephanie R. Brockman;Sarah F. Paternoster;Nancy D. Bone

  • VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia

    Yean K. Lee;Nancy D. Bone;Ann K. Strege;Tait D. Shanafelt

  • Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

    Unknown

  • Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

    Anne J. Novak;Richard J. Bram;Neil E. Kay;Diane F. Jelinek

  • Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

    Diane F. Jelinek;Renee C. Tschumper;Susan M. Geyer;Nancy D. Bone

  • Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

    Anne J. Novak;Deanna M. Grote;Mary Stenson;Steven C. Ziesmer

  • IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

    Jun Won Lee;Ho Yeon Chung;Lori A. Ehrlich;Diane F. Jelinek

  • Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Tim G. Call;Clive S. Zent;Betsy LaPlant

  • Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

    Wee J. Chng;Roelandt F. Schop;Tammy Price-Troska;Irene Ghobrial

  • Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Thomas E. Witzig;Paul J. Kurtin;Jeff A. Sloan

  • CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin’s Lymphoma Predicts Patient Outcome

    Stephen Maxted Ansell;M. Stenson;Thomas Matthew Habermann;Diane F Jelinek

Frequent Co-Authors

Neil E. Kay
Neil E. Kay Mayo Clinic
Tait D. Shanafelt
Tait D. Shanafelt Stanford University
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Susan L. Slager
Susan L. Slager Mayo Clinic
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Gordon W. Dewald
Gordon W. Dewald Mayo Clinic
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Šárka Pospíšilová
Šárka Pospíšilová Masaryk University
Rafael Fonseca
Rafael Fonseca Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Nursing degrees, for instance, offer a strong foundation in patient care and biological sciences, which complement immunological knowledge.

If you’re transitioning into nursing from another field, programs like the best online bsn programs for non nurses provide flexible, reputable pathways. These programs are designed to accommodate non-traditional students and build essential nursing skills efficiently.

For faster entry into nursing, the easiest absn programs to get into offer accelerated formats with more straightforward admission requirements, ideal for those seeking to launch their nursing career quickly.

Entry-level nursing roles can be pursued via lpn programs with easiest admission requirements, which provide vital clinical experience and a gateway to advanced practice. These programs are accessible and can lead to impactful positions in healthcare settings.

For advanced practice roles, consider the easiest nurse practitioner program, allowing nurses to expand their scope of practice with a more manageable admission process. These programs are well-suited for immunology professionals aiming to influence patient outcomes through specialized knowledge.

Best Scientists Citing Diane F. Jelinek

Trending Scientists

Recently Published Articles